Aptevo Therapeutics Inc
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune … Read more
Aptevo Therapeutics Inc (APVO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.385x
Based on the latest financial reports, Aptevo Therapeutics Inc (APVO) has a cash flow conversion efficiency ratio of -0.385x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.69 Million) by net assets ($17.39 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Aptevo Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Aptevo Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Aptevo Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aptevo Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Da Hui Limited
TWO:5276
|
0.046x |
|
Terra Uranium Ltd
AU:T92
|
-0.155x |
|
Ginting Jaya Energi
JK:WOWS
|
0.023x |
|
Willings Co. Ltd
KQ:313760
|
-0.012x |
|
Oshidori International Holdings Limited
PINK:OSHDF
|
0.001x |
|
Wide Open Agriculture Ltd
AU:WOA
|
-0.091x |
|
Krynica Vitamin SA
WAR:KVT
|
0.004x |
|
Masivo Silver Corp
PINK:GNYPF
|
-0.991x |
Annual Cash Flow Conversion Efficiency for Aptevo Therapeutics Inc (2014–2024)
The table below shows the annual cash flow conversion efficiency of Aptevo Therapeutics Inc from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $4.75 Million | $-23.79 Million | -5.002x | -421.15% |
| 2023-12-31 | $12.22 Million | $-11.73 Million | -0.960x | +17.93% |
| 2022-12-31 | $17.97 Million | $-21.02 Million | -1.170x | +93.44% |
| 2021-12-31 | $1.22 Million | $-21.68 Million | -17.828x | -909.07% |
| 2020-12-31 | $16.59 Million | $-29.32 Million | -1.767x | +50.64% |
| 2019-12-31 | $11.84 Million | $-42.38 Million | -3.579x | -111.63% |
| 2018-12-31 | $30.41 Million | $-51.42 Million | -1.691x | -233.72% |
| 2017-12-31 | $82.03 Million | $-41.57 Million | -0.507x | +30.48% |
| 2016-12-31 | $50.57 Million | $-36.86 Million | -0.729x | -32.49% |
| 2015-12-31 | $88.62 Million | $-48.76 Million | -0.550x | -10.74% |
| 2014-12-31 | $94.61 Million | $-47.01 Million | -0.497x | -- |